Twice-weekly Ixazomib plus Lenalidomide-dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Long-term Follow-up Data for Patients Not Undergoing Stem Cell Transplantation (SCT)

Addition of a proteasome inhibitor (PI) to a doublet backbone therapy improves efficacy in NDMM patients. Results of a phase 1/2 study of the oral PI ixazomib given weekly in combination with Rd in NDMM were published previously.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Paul Richardson, Craig Hofmeister, Cara Rosenbaum, Myo Htut, David Vesole, Jesus Berdeja, Michaela Liedtke, Ajai Chari, Stephen Smith, Daniel Lebovic, Noopur Raje, Eileen Liao, Xiaoquan Zhang, Deborah Berg, Rachid Baz Source Type: research